Straumann shareholders approve all proposals of the Board of Directors at AGM 

  • Annual Report approved; consent on Compensation Report
  • All Directors re-elected
  • Dividend approved together with return of reserved capital contributions bringing overall payout to CHF 3.75 per share (dividend yield: 2.4%)


Basel, 4 April 2012: At Straumann’s Annual General Meeting (AGM) today in Basel, the shareholders approved all the proposals put forward by the Board of Directors. 491 shareholders attended the meeting and a total of 10 166 573 voting shares were represented, corresponding to 65% of the overall share capital.


Annual Report and Compensation Report approved

The shareholders approved the 2011 Annual Report, the 2011 Financial Statements and the discharge of the Board of Directors for their activities in 2011. In an advisory vote, they also consented to the 2011 Compensation Report, which includes a new remuneration model.


PricewaterhouseCoopers of Basel was reappointed as Statutory Auditors and Group Auditors for a further term of one year.


Board of Directors confirmed

All the Directors of the Straumann Board – Gilbert Achermann (Chairman), Dr Sebastian Burckhardt, Dominik Ellenrieder, Roland Hess, Ulrich Looser, Dr Beat Lüthi, Stefan Meister and Dr h.c. Thomas Straumann (Vice Chairman) – were re-elected for a further one-year term of office.


Stable dividend

The meeting approved the appropriation of the available earnings. CHF 34 million were allocated to the 2011 dividend, corresponding to CHF 2.20 per share. The shareholders also approved the use of CHF 24 million to pay CHF 1.55 of the total dividend per share out of ‘reserves for capital contributions’. Thus, Straumann is maintaining the same payout as in previous years, resulting in a dividend yield of 2.4%. The payout of CHF 3.75 per share will be made as of 13 April 2012.


2013 AGM

The next ordinary general meeting of Straumann’s shareholders will be convened on 5 April 2013 at the Basel Congress Center.


About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2450 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners.